Collegium Pharmaceutical, Inc. COLL R2K
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
READ MORE ›$33.61
+15.34% 1Y
Market & Price
Market Cap
$1.09B
Current Price
$33.61
High / Low (52W)
$49.84 / $29.14
Beta
0.76
Valuation
Stock P/E
16.32
Industry PE
23.65
Forward P/E
4.42
PEG Ratio
-
Book Value
$9.64
Price to Book
3.49
P/S
1.37
EV/EBITDA
3.76
Dividend Yield
-
Profitability & Returns
ROCE
14.38%
ROE
27.41%
ROA
7.60%
Profit Margin
9.41%
Op Margin
15.96%
EPS (Latest Qtr)
$0.40
EPS (TTM)
$2.06
Balance Sheet & Liquidity
Debt/Equity
2.98
Quick Ratio
1.50
Current Ratio
1.71
Debt
$929.69M
Total Assets
$1.66B
Current Assets
$691.41M
Working Capital
$251.38M
Ownership
Promoter Holding
1.16%
Chg in Prom Hold
-
FII / Inst Holding
127.59%
Chg in FII Hold
-0.01%
Financial Snapshot
Enterprise Value
$1.60B
Total Revenue (TTM)
$796.33M
EBITDA
$425.05M
Free Cash Flow
$332.62M
Operating Cash Flow
$331.04M
Shares Outstanding
32.43M
Gross Margin
89.17%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
18.94%
Profit 5Y
117.15%
Revenue (YoY)
8.90%
Earnings (YoY)
-46.60%
PROS
- Strong return on equity of 27.4%.
- Compounding revenue at 18.9% over 5 years.
- Profit CAGR of 117.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 32.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COLL Collegium Pharmaceutical, Inc. R2K | 33.61 | 16.32 | $1.09B | - | 14.38% | 27.41% | 18.94% | 117.15% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 2.17M | 3.56M | 11.95M | 10.79M | 63.75M | 73.06M | 70.18M | 73.43M | 74.52M | 75.04M | 72.94M | 74.20M | 76.51M | 78.06M | 79.18M | 76.27M | 87.72M | 82.94M | 78.84M | 27.36M | 83.75M | 123.55M | 127.01M | 129.62M | 144.77M | 135.55M | 136.71M | 149.75M | 144.92M | 145.28M | - | - | 177.76M | 188.00M | 209.36M | 205.45M | 193.52M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.43M | 79.62M | 80.19M | 77.07M | 76.27M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 25.35M | 26.39M | 26.19M | 25.11M | 38.99M | 48.36M | 48.19M | 44.29M | 55.60M | 50.24M | 46.11M | -1.33M | 48.50M | 52.36M | 58.84M | 49.79M | 77.40M | 73.83M | 80.31M | 94.63M | 91.46M | 90.81M | - | - | 97.32M | 108.38M | 129.17M | 128.38M | 117.25M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 76.42M | 73.64M | 67.10M | 67.64M | 86.35M |
| Operating Income | -24.47M | -26.44M | -27.58M | -23.18M | -21.26M | -13.43M | -17.58M | -13.21M | -7.29M | -11.19M | 11.00M | -9.99M | -5.01M | -6.38M | -2.37M | 5.06M | 16.55M | 19.63M | 15.00M | 21.19M | 16.41M | 14.15M | -34.12M | -10.02M | 11.11M | 20.47M | 11.76M | 24.63M | 35.63M | 45.01M | 61.69M | 49.47M | 47.47M | - | - | 20.90M | 34.75M | 62.07M | 60.74M | 30.90M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.48M | 94.10M | 121.71M | 104.72M | 90.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.79M | 20.46M | 21.77M | 19.29M | 15.86M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.12M | 17.02M | 43.44M | 29.04M | 18.74M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 705.00K | 5.04M | 11.93M | 12.07M | 4.24M |
| Net Income | -24.52M | -26.44M | -27.56M | -23.08M | -21.12M | -13.26M | -17.40M | -18.65M | -13.06M | -16.50M | 9.09M | -9.70M | -4.71M | -6.11M | -2.20M | 450.00K | 8.06M | 11.29M | 6.96M | 15.66M | 72.84M | 8.05M | -25.03M | -13.07M | -5.19M | 457.00K | -7.20M | -17.43M | 13.01M | 20.63M | 31.94M | 27.71M | 19.61M | - | - | 2.42M | 11.98M | 31.51M | 16.96M | 14.50M |
| Diluted EPS | - | - | - | - | - | - | - | -0.57 | -0.40 | -0.50 | 0.27 | -0.29 | -0.14 | -0.18 | - | 0.01 | 0.23 | 0.32 | 0.20 | 0.41 | 1.79 | 0.22 | -0.73 | -0.39 | -0.15 | 0.01 | -0.21 | -0.51 | 0.34 | 0.53 | 0.82 | 0.71 | 0.52 | - | - | 0.07 | 0.34 | 0.84 | 0.46 | 0.40 |
| R&D Expense | 4.30M | 3.25M | 3.33M | 2.13M | 2.18M | 2.07M | 2.19M | 2.27M | 2.24M | 1.91M | 2.25M | 2.99M | 2.46M | 2.49M | 2.40M | 2.67M | 2.49M | 2.14M | 2.47M | 2.93M | 3.46M | 1.45M | 1.61M | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.71M | 28.48M | 280.41M | 296.70M | 310.02M | - | 463.93M | 566.77M | 631.45M | 780.57M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 254.44M | 240.60M | 254.10M | 317.31M |
| Gross Profit | - | - | - | - | - | 114.74M | 103.04M | 179.84M | - | 209.49M | 326.17M | 377.34M | 463.26M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 176.17M | 159.21M | 210.36M | 284.80M |
| Operating Income | -16.04M | -17.66M | -26.91M | -94.08M | -75.45M | -20.68M | -23.75M | 56.23M | - | 33.32M | 166.96M | 166.98M | 178.45M |
| EBITDA | - | - | - | - | - | - | - | - | - | 173.31M | 308.33M | 341.70M | 401.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 63.21M | 83.34M | 73.97M | 82.31M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -28.85M | 75.73M | 98.57M | 92.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -3.85M | 27.58M | 29.38M | 29.75M |
| Net Income | -16.20M | -17.92M | -27.25M | -94.18M | -74.86M | -39.13M | -22.72M | 26.75M | - | -25.00M | 48.16M | 69.19M | 62.87M |
| Diluted EPS | - | - | - | - | - | -1.19 | -0.68 | 0.76 | - | -0.74 | 1.29 | 1.86 | 1.73 |
| R&D Expense | 14.16M | 14.96M | 7.97M | 14.95M | 8.57M | 8.66M | 10.34M | 9.77M | 9.45M | 3.98M | 0 | 0 | - |
Compounded Sales Growth
| 5 Years: | 18.94% |
| 1 Year: | 8.90% |
Compounded Profit Growth
| 5 Years: | 117.15% |
| 1 Year: | -46.60% |
Stock Price Performance
| 1 Year: | +15.34% |
| 6 Months: | -26.29% |
| 3 Months: | -19.34% |
| 1 Month: | -0.44% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.09M | 97.72M | 162.02M | 135.57M | 291.25M | 306.30M | 643.84M | - | 1.17B | 1.14B | 1.66B | 1.66B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 419.99M | 537.60M | 482.26M | 691.41M |
| Cash & Equivalents | 11.94M | 7.55M | 1.63M | 95.70M | 153.22M | 118.70M | 146.63M | 170.02M | 174.12M | - | 173.69M | 238.95M | 70.56M | 231.25M |
| Inventory | - | - | - | - | - | - | - | - | - | - | 46.50M | 32.33M | 35.56M | 40.91M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 183.12M | 179.53M | 228.54M | 211.33M |
| Total Liabilities | - | - | 17.33M | 12.65M | 27.11M | 31.49M | 199.66M | 218.87M | 457.81M | - | 979.29M | 947.88M | 1.43B | 1.36B |
| Current Liabilities | - | - | 10.42M | 8.43M | 25.60M | 31.49M | 189.13M | 201.76M | 239.45M | - | 433.73M | 457.92M | 509.51M | 440.03M |
| Long Term Debt | - | - | - | - | 4.15M | - | 11.50M | 11.50M | - | - | 538.45M | 483.84M | 787.90M | 780.33M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 709.17M | 674.28M | 859.30M | 814.86M |
| Total Equity | -61.40M | -68.22M | -89.35M | 85.07M | 134.91M | 104.08M | 91.58M | 87.43M | 186.03M | - | 194.84M | 195.43M | 228.84M | 301.68M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 37.08M | 38.19M | 39.65M | 40.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -21.57M | -75.05M | -67.02M | 169.39M | 27.78M | 93.94M | - | 124.23M | 274.75M | 204.98M | 329.32M |
| Investing Cash Flow | - | - | -362.00K | -2.98M | -990.00K | -24.35M | -6.44M | -373.77M | - | -573.69M | -70.81M | -287.76M | -63.53M |
| Financing Cash Flow | - | - | 115.99M | 135.56M | 33.48M | -117.20M | 2.04M | 286.47M | - | 436.72M | -140.18M | -60.60M | -110.25M |
| Capital Expenditure | -206.00K | -8.00K | -362.00K | -477.00K | -990.00K | -5.48M | -6.44M | -5.55M | - | -1.62M | -461.00K | -1.65M | -1.74M |
| Free Cash Flow | - | - | -21.93M | -75.53M | -68.01M | 163.91M | 21.34M | 88.40M | - | 122.61M | 274.29M | 203.33M | 327.58M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -12.74M | 63.76M | -143.38M | 155.55M |
| Share Buybacks | - | - | - | - | - | - | - | - | 47.86M | 14.06M | 75.00M | 60.02M | 25.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 40.9% | 34.7% | 58.0% | - | 45.2% | 57.5% | 59.8% | 59.3% |
| Operating Margin % | - | - | - | -5,498.7% | -264.9% | -7.4% | -8.0% | 18.1% | - | 7.2% | 29.5% | 26.4% | 22.9% |
| Net Margin % | - | - | - | -5,504.1% | -262.9% | -14.0% | -7.7% | 8.6% | - | -5.4% | 8.5% | 11.0% | 8.1% |
| ROE % | 23.7% | 20.1% | -32.0% | -69.8% | -71.9% | -42.7% | -26.0% | 14.4% | - | -12.8% | 24.6% | 30.2% | 20.8% |
| ROCE % | - | 331.6% | -30.1% | -69.0% | -72.5% | -20.3% | -22.7% | 13.9% | - | 4.5% | 24.4% | 14.5% | 14.7% |
Shareholding Pattern
Insiders
1.16%
Institutions
127.59%
Public Float
129.09%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.83% | 5.13M | $172.55M |
| 2 | Janus Henderson Group PLC | 5.63% | 1.83M | $61.36M |
| 3 | Invesco Ltd. | 4.91% | 1.59M | $53.50M |
| 4 | Fuller & Thaler Asset Management Inc. | 4.62% | 1.50M | $50.40M |
| 5 | Renaissance Technologies, LLC | 4.53% | 1.47M | $49.39M |
| 6 | State Street Corporation | 4.39% | 1.42M | $47.88M |
| 7 | Eventide Asset Management LLC | 4.39% | 1.42M | $47.87M |
| 8 | Massachusetts Financial Services Co. | 4.21% | 1.37M | $45.91M |
| 9 | Vanguard Capital Management LLC | 4.11% | 1.33M | $44.84M |
| 10 | Principal Financial Group, Inc. | 3.99% | 1.30M | $43.53M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COLL
No recent headlines available.